National Academies Press: OpenBook

Medical Isotope Production Without Highly Enriched Uranium (2009)

Chapter: Appendix D: Alternative Molybdenum-99 Production Processes

« Previous: Appendix C: Presentations and Visits
Suggested Citation:"Appendix D: Alternative Molybdenum-99 Production Processes." National Research Council. 2009. Medical Isotope Production Without Highly Enriched Uranium. Washington, DC: The National Academies Press. doi: 10.17226/12569.
×
Page 184
Suggested Citation:"Appendix D: Alternative Molybdenum-99 Production Processes." National Research Council. 2009. Medical Isotope Production Without Highly Enriched Uranium. Washington, DC: The National Academies Press. doi: 10.17226/12569.
×
Page 185
Suggested Citation:"Appendix D: Alternative Molybdenum-99 Production Processes." National Research Council. 2009. Medical Isotope Production Without Highly Enriched Uranium. Washington, DC: The National Academies Press. doi: 10.17226/12569.
×
Page 186
Suggested Citation:"Appendix D: Alternative Molybdenum-99 Production Processes." National Research Council. 2009. Medical Isotope Production Without Highly Enriched Uranium. Washington, DC: The National Academies Press. doi: 10.17226/12569.
×
Page 187
Suggested Citation:"Appendix D: Alternative Molybdenum-99 Production Processes." National Research Council. 2009. Medical Isotope Production Without Highly Enriched Uranium. Washington, DC: The National Academies Press. doi: 10.17226/12569.
×
Page 188
Suggested Citation:"Appendix D: Alternative Molybdenum-99 Production Processes." National Research Council. 2009. Medical Isotope Production Without Highly Enriched Uranium. Washington, DC: The National Academies Press. doi: 10.17226/12569.
×
Page 189

Below is the uncorrected machine-read text of this chapter, intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text of each book. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Appendix D Alternative Molybdenum-99 Production Processes T here are two primary processes for producing molybdenum-99 (Mo-99): fission of uranium-235 (U-235) and neutron capture of molybdenum-98 (Mo-98). These are shown schematically in Figures D.1 and D.2, respectively. The fission of U-235 produces a large number of fission products, including Mo-99. The mass distribution of these fission products is shown in Figure 2.5. The rate of production, which is of interest here, is proportional to several conditions as illustrated in the equation below: R∝nφσ where R = rate of reaction (i.e., number of reactions per unit time and volume), which is related to the amount of the new substance that can be produced n = the number of target nuclei present (i.e., the target nuclei density in atoms per unit volume) φ = the flux of particles causing the reaction (neutrons per cm2 per second) σ = the probability that the reaction will occur, expressed as an area To understand whether a particular method is better than another these parameters must be considered as illustrated in the following comparisons. 184

APPENDIX D 185 99 Mo N 235 236 U U Other FPs N FIGURE D.1 Schematic representation of the uranium-235 fission process. N = neutrons and FPs = fission products. Figure D-1 99 Mo 98 99 Mo Mo N FIGURE D.2 Production of Mo-99 from neutron capture. N = neutron. 98Mo(n,γ)99Mo Figure D-2 The most commonly used alternative method for producing Mo-99 involves the neutron capture on an enriched target of Mo-98 (natural o ­ ccurrence of Mo-98 is 24.13 percent), which is illustrated schematically in Figure D.2. The fission cross section for thermal fission of U-235 is approximately 600 barns which represents a very high probability. Of this, approximately   1 barn = 1 × 10–24 cm2.

186 APPENDIX D 6.1 percent results in the production of Mo-99 or about 37 barns. The pro- duction cross section for the 98Mo(n,γ)99Mo reaction is about 0.13 barn for thermal neutrons, a factor of almost 300 less than the fission process even accounting for the 6.1 percent fission yield for Mo-99. There are 6 stable isotopes (92, 93, 94, 95, 96, 97) of Mo and two very long-lived isotopes (98 is >1012 years and 100 is >1018 years). Both Mo-98 and Mo-100 have long enough half-lives that they exist in nature and can be used as target material. Thus the ability to produce large amounts of Mo-99 from the direct reaction route would depend upon the availability of a high flux reactor that could compensate for the lower cross section. For example, typical fluxes from the National Research Universal (NRU) reactor are around 1.5 × 1014 neutrons per cm2 per second while the High Flux Isotope Reactor (HFIR) at Oak Ridge has a flux of 1015 neutrons per cm2 per second, more than enough to be competitive in producing large amounts of Mo-99 via the (n,γ) approach. However, these additional neutrons are not free and would add to the costs of producing Mo-99 by this method. However, the Mo-99 produced by this process has a very low specific activity, because most of the Mo in the product is Mo-98. The ­ specific activity for fission-produced Mo-99 is two to four orders of magnitude higher than from the neutron capture process (Ottinger and Collins, 1996). This has practical implications for using neutron capture Mo-99 in med- ical isotope procedures: First, the technetium generators that are used for ­ fission-produced Mo-99 would have to be redesigned to use neutron c ­ apture-produced Mo-99. A larger technetium generator column would be needed, which would increase the size of the generator and the size and weight of its shield. A larger volume of liquid would be required to elute Tc-99m from the column, which would require all of the current Tc-99m kits (e.g., see Table 2.1) to be reformulated. In addition, the useful lifetime of the generator would be reduced due to the potential for higher break- through of the Mo-99. This would require users to purchase additional generators.   If desired, the isotope could also be enriched in Mo-98 using mass separation processes.   Specific activity is defined as the amount of radioactivity per unit mass as is usually e ­ xpressed in terms of Becquerel’s per gram or curies per gram.   Delft University researchers are examining the feasibility of using Szilard Chalmers ­reactions to increase specific activities. However, the yields from this process are likely to be small, and a great deal of development work would likely be required to get to a useful, practical process, if indeed it is possible at all. See http://www.tudelft.nl/live/pagina.jsp?id=29b23a65-485b-44ee- 9210-f460e363c2c6&lang=en. Accessed October 23, 2008.   When the generator is eluted to obtain Tc-99m a very small amount of Mo-99 is released. The generator can no longer be used when the amount of Mo-99 in the eluted solution e ­ xceeds a certain level. The amount of breakthrough is roughly proportional to the amount of ­molybdenum present, both radioactive Mo-99 and nonradioactive Mo-98.

APPENDIX D 187 TABLE D.1 Comparison of Fission and Neutron Produced 99Mo 235U(n,f)99Mo 98Mo(n,γ)99Mo 99Mo Produces high specific activity Produces low specific activity Mo-99 Requires enriched 235U target Requires highly enriched Mo-98 target Complex chemical processing Simple chemical processing Requires dedicated processing facility Requires high flux neutron source Generates high-level radioactive waste Generates minimal waste SOURCE: Modified from S. Mirzadeh, Oak Ridge National Laboratory. Table D.1 compares the two methods of production. Another point to consider, although of secondary importance, is the fact that several other radionuclides of medical importance are coproduced in the fission process and would require an alternative source (in particular ���������������������� 131I and 133Xe) in the case of a neutron capture process. T����������������������������������������������������������������� o make use of the neutron capture approach a number of technical challenges must be overcome not the least of which is the availability of the desired Tc-99m in a useful chemical form and of the same quality as the fission product for use with the many radiopharmaceutical kits now on the market. This point applies for all of the alternative processes dis- cussed below. Accelerator production There have been a number of proposals for accelerator production of Mo-99 as well as for direct production of Tc-99m. One accelerator-based approach essentially mimics the reactor production route in that the acceler- ator becomes the source of neutrons, which are then used to produce fission in a blanket of U-235 surrounding the neutron source. The required fluxes would be difficult to achieve in the required geometry to be competitive with reactor-generated neutrons. Such an accelerator would be expensive to build and operate although less expensive than a new reactor. Another ­approach would be to use an electron beam to generate high-­intensity ­photons which in turn would be used to initiate a nuclear reaction on enriched Mo such that 100Mo(γ,n)99Mo creates the desired product (TRIUMF, 2008). The same issues as discussed above holds for this approach in addition to the technical challenges associated with producing a high-energy electron machine with sufficient beam flux to be able to produce sufficient Mo-99 to be competi- tive. That said, there are discussions around the design of electron linacs capable of accelerating tens of milliamps of electrons. For both of these accelerator approaches multiple machines would be required since the fluxes of neutrons and photons would not be sufficiently

188 APPENDIX D high to be competitive with a reactor. The cost of construction and opera- tion of multiple machines would have to be analyzed to determine if a busi- ness case could be made for these approaches. Another approach is photo-fission of U-238 using natural or depleted uranium targets. The challenge is the same as is mentioned for the other photon induced reaction (100Mo(γ,n)99Mo); that is, the need for a very high intensity beam to overcome the factor of about 1000 smaller cross section for this reaction versus neutron fission of U-235, although the fission yields are almost identical (approximately 6 percent). The other option that has been explored is the direct production of Tc-99m from the 100Mo(p,2n)99mTc. The biggest disadvantage with this approach is that the final product (the one used in nuclear medicine pro- cedures) is directly produced and has a short half-life (6 hours). Thus, its usefulness would be greatly hampered if it needed to be shipped great dis- tances to the end users. Even a network of suppliers would face a challenge. Takács et al. (2002) report that the cross section for the direct production of Tc-99m from enriched Mo-99 would be approximately 17 mCi/µAh. At this level even a very high beam current facility (500µA protons) and irra- diation periods of a day (i.e., 24 hours), the most that could be produced in a single facility would be < 200 Ci per day. To meet the needs of the United States there would have to be more than 25 cyclotrons dedicated to this process. This does not take into account the losses associated with transport and chemical efficiencies for separating the Tc-99m from the target matrix. A single site might be able to become self-sufficient but this would not help the larger community. Takács et al. (2002, 2003) explored the production of Mo-99 from the 100Mo(p,pn)99Mo reaction. Their results indicated a thick target yield (40–45 MeV) of 3.8 mCi/µAh. The daily production for a similar cyclotron would be about 50 Ci thus about 100 cyclotrons would be required for this approach. The other approach would be through the spallation (high-energy projectile collides with the target nucleus with enough energy that a very large array of products is produced) of a target to produce Mo-99. The production rate of Mo-99 from most reasonable target materials would be at best many orders of magnitude lower than the reactor methods and two orders of magnitude lower than the above accelerator reactions and thus not a viable approach. From this analysis there are few viable alternative approaches to the supply of Mo-99 or Tc-99m for widespread distribution. With the termina­ tion of the Maple reactor project, alternative approaches need to be ­explored in comparison to the cost of constructing and commissioning a new reactor facility, especially with photon-induced fission with U-238.

APPENDIX D 189 REFERENCES Ottinger, C. L., and E. D. Collins. 1996. Assessment of Potential ORNL Contributions to Sup- ply of Molybdenum-99. Oak Ridge National Laboratory Report No. ORNL/TM-13184. Oak Ridge, TN: ORNL. Takács, S., F. Tárkányi, M. Sonck, and A. Hermanne. 2002. Investigation of the natMo(p,x)96mgTc nuclear reaction to monitor proton beams: New measurements and consequences on the earlier reported data. Nucl Instrum Methods Phy Res B 198:183-196. Takács, S., Z. Szűcs, F. Tárkányi, A. Hermanne, and M. Sonck. 2003. Evaluation of proton induced reactions on 100Mo: New cross sections for production of 99mTc and 99Mo. Radioanal Nucl Chem 257:195-210. TRIUMF. 2008. Making Medical Isotopes: Report of the Task Force on Alternatives for Medical-Isotope Production. Available at http://admin.triumf.ca/facility/5yp/comm/­ Report-vPREPUB.pdf.

Next: Appendix E: Correspondence with Atomic Energy of Canada Limited »
Medical Isotope Production Without Highly Enriched Uranium Get This Book
×
 Medical Isotope Production Without Highly Enriched Uranium
Buy Paperback | $65.00 Buy Ebook | $54.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

This book is the product of a congressionally mandated study to examine the feasibility of eliminating the use of highly enriched uranium (HEU2) in reactor fuel, reactor targets, and medical isotope production facilities. The book focuses primarily on the use of HEU for the production of the medical isotope molybdenum-99 (Mo-99), whose decay product, technetium-99m3 (Tc-99m), is used in the majority of medical diagnostic imaging procedures in the United States, and secondarily on the use of HEU for research and test reactor fuel.

The supply of Mo-99 in the U.S. is likely to be unreliable until newer production sources come online. The reliability of the current supply system is an important medical isotope concern; this book concludes that achieving a cost difference of less than 10 percent in facilities that will need to convert from HEU- to LEU-based Mo-99 production is much less important than is reliability of supply.

READ FREE ONLINE

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  6. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  7. ×

    View our suggested citation for this chapter.

    « Back Next »
  8. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!